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Hepatitis B vaccine and multiple sclerosis: A case of repeated de´ja` vu?
To the Editor:
I cannot agree more with Braillon [1] that in revealing
the results of any study concerning the adverse reactions
of treatment or prevention measures, everyone in the
chain of releasing the information should be very pru-
dent. This is especially true in relation to the hepatitis
B vaccine.
The unusually low coverage of hepatitis B vaccina-
tion in France can be traced to the alleged concerns
about the safety of the hepatitis B vaccine. The allega-
tion started right after the country implemented an
active hepatitis B vaccination program in 1994–1995 tar-
geting at pre-adolescents in the ﬁrst year of secondary
schools as well as all infants [2]. Initially, the program
was highly successful with a coverage rate of 76% in
adolescents. During implementation of the program,
reports of demyelinating disorders of the central nervous
system (CNS) suspected to be associated with hepatitis
B vaccination started to appear. Despite the lack of cau-
sal association, the issue caught the attention of mass
media and, naturally, the general public then. The pres-
sure cumulated became so great that it led the French
health authority to suspend hepatitis B vaccination in
a school-based program on October 1, 1998. The French
government’s decision was immediately condemned by
the World Health Organization (WHO) and the French
pediatricians [3], because it will very possibly result in a
loss of public conﬁdence in hepatitis B vaccination, and
thus lead other countries to discontinue its use or decide
not to introduce a hepatitis B vaccination program that
is critical in the control of hepatitis B worldwide [4].
Indeed, the negative impact could be tremendous, if
not handled appropriately. To avoid unnecessary
negative impacts to our very successful mass hepatitis
B vaccination program in Taiwan [5], right after the sus-
pension of hepatitis B vaccine in France, Taiwan’s
Department of Health immediately issued a press release
to assure the safety and necessity of hepatitis B vaccina-
tion in the country. Fortunately, the French issue did
not ferment, and did not aﬀect our program.
A premature or immature release of the results of any
study concerning adverse reactions of the hepatitis B vac-
cines may be exploited by anti-vaccination groups, liabil-
ity lawyers, and most importantly, the media. Even if the
results are disproved ﬁnally, the media usually does not
report them, because of the loss of news worthiness [6].
The public’s initial wrong image remains, and becomes
an obstacle in the implementation of the vaccination pro-
gram. Unfortunately, despite the rejection of a causal
relationship between hepatitis B vaccine and multiple
sclerosis [7], reports suggesting a risk of multiple sclerosis
associated with recombinant hepatitis B vaccine still ap-
peared [8]. WHO responded quickly by denying the inter-
pretation of the results of the study [WHO Global
Advisory Committee on Vaccine Safety, September
2004; http://www.who.int/vaccine_safety/topics/hepati-
tisb/multiple_sclerosis/sept_04/en/]. The issue recurred
again recently, initiated after an article published by a
French group in early October 2008 [9]. Based on sub-
group analysis of children having followed the French
vaccine recommendations, it was concluded that
althoughhepatitis B vaccination does not increase the risk
of CNS inﬂammatory demyelination in children, the
Engerix hepatitis B vaccine appears to increase the risk,
especially for the conﬁrmed cases of multiple sclerosis.
Although the authors conceded that their results require
conﬁrmation in future studies [9], the conclusions of the
article very likely have had exerted another negative im-
pact on hepatitis B vaccination, at least in France. The
Global Advisory Committee on Vaccine Safety of WHO
again responded immediately by concluding that the
study did not provide convincing evidence that hepatitis
B vaccine, or use of any brand of the vaccine, is associated
with an increased risk of acute CNS inﬂammatory demy-
elination or multiple sclerosis [WHO Global Advisory
Committee on Vaccine Safety, October 8, 2008; http://
www.who.int/vaccine_safety/topics/hepatitisb/multiple_
sclerosis/oct_2008/en]. In the meantime, the French
health products safety agency (Afssaps) also responded
promptly in refuting the association [http://www.
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Hopefully, these counteractions will alleviate the low cov-
erage of hepatitis B vaccine in the country.
In the real world, there is no perfect means for a given
treatment or prevention that bears no risk. In hepatitis
B, any presumed risk of untoward events possibly asso-
ciated with hepatitis B immunoprophylaxis should be
weighed against the disease burden caused by the hepa-
titis B virus. Education of the public and health profes-
sionals is essential [10], and it should include everyone in
the chain of releasing the information, right from the
sources all the way down to academia and the public.
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On the role of platelets in the pathogenesis of viral hepatitis
To the Editor:
We read with interest the commentary by Ulrich
Spengler [1] where he evaluated a recent manuscript
by Lang et al. [2] on the role of platelet-derived seroto-
nin in the pathogenesis of viral hepatitis. We were
somewhat surprised to see that work constituting the
foundation of the above-mentioned study was not ci-
ted. A few years ago our group started investigating
the role of platelets in the pathogenesis of viral hepati-
tis, using diﬀerent mouse models that include trans-
genic mice replicating hepatitis B virus (HBV) at high
levels in the hepatocyte and mice infected with hepato-
tropic adenoviruses and arenaviruses (i.e. lymphocytic
choriomeningitis virus [LCMV]). Similar to humans in-
fected with HBV or hepatitis C virus (HCV), liver dis-
ease in these models is mostly a consequence of the
virus-speciﬁc CD8 T cell response aimed at viral clear-
ance. We found that platelets play a previously unrec-
ognized role in viral hepatitis. Upon activation,
platelets contribute to liver disease and viral clearance
by promoting the recruitment of virus-speciﬁc cytotoxic
T lymphocytes (CTL) into the liver [3]. Further exper-
iments suggested that this eﬀect depends on speciﬁc
interactions between platelets and CTL likely occurring
within the hepatic microcirculation and helping CTL to
extravasate, reach target cells and perform pathogenic
and antiviral eﬀector functions [4–6]. We conﬁrmed
these results in follow-up studies by showing reduction
of hepatic CTL recruitment after pharmacological inhi-
bition of platelet activation [7]. The paper by Lang
et al. nicely reiterates a role for platelets in the patho-
genesis of liver disease and provides a novel mechanis-
tic hint. They identiﬁed serotonin as a potential
molecular mediator of CTL recruitment and liver dam-
age in LCMV-infected mice. Although the use of
LCMV as a model for human HBV and HCV infection
must be taken cautiously (unlike HBV and HCV that
infect hepatocytes almost exclusively, LCMV infects
primarily non-parenchymal cells of the liver such as
Kupﬀer cells [8]), the study by Lang et al. raises impor-
tant questions. Where does serotonin come from dur-
ing liver inﬂammation? Is it platelet-derived as the
authors seem to suggest? What cells respond to seroto-
nin? What serotonin receptors are involved? The
answers to these questions are important if we envisage
future manipulations of serotonin-dependent pathways
